Browse diseases

…Background Clinical guidelines for relapsing remitting multiple sclerosis (RRMS) do not recommend disease modifying therapy (DMT) escalat…

…tained real-world effectiveness of natalizumab in patients with RRMS ( NCT00493298).…

…lizumab/rituximab in a real-world cohort of relapsing-remitting multiple sclerosis (RRMS) patients using data from the Middle East and North Afric…

…and Methods The patient was a 33-year-old woman, diagnosed with RRMS in 2012. She had previously received several DMTs (interferon b…

…lation cannot be recommend as a universal treatment strategy in RRMS. The decision to de-escalate should be considered on an individ…

…ion (aHSCT) represents a treatment option for highly aggressive multiple sclerosis (MS). Here, we report outcome analyses from the two largest Ger…

…s increasingly used as an outcome measure in clinical trials in relapsing-remitting multiple sclerosis (RRMS), but little is known about how chronological age interac…

…est that cladribine is an effective option for the treatment of RRMS, although continuous monitoring and individualised treatment ad…

…s two UK centres (Cardiff, Cambridge), we studied patients with RRMS who received at least 2 cycles of alemtuzumab and at least 1 fo…

…are with respect to reduction in brain atrophy in patients with relapsing remitting multiple sclerosis (RRMS).Methods We searched the EMBASE, MEDLINE and COCHRANE dat…

…Background Multiple sclerosis (MS) progression independent of relapses is driven by brain inn…

…Background The main goal of treatment in relapsing-remitting multiple sclerosis (RRMS) is to reduce the occurrence of relapses. However, little…